rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    BVS
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      What Bioventus Shareholders Got Right
      Nov 7Yahoo FinanceBVS
      Bioventus (BVS) Stock Price Slides After Q3 Results Cut Revenue Outlook

      Bioventus walked into this Q3 2026 report with a stock already under pressure, and it just took another hit. Shares closed at US$13.15 before the release and then slumped about 17% to roughly US$10.95 as investors reacted in real time. The headline result looked steadier than the price suggests. Management kept full year adjusted earnings per share guidance unchanged, while adjusted EBITDA margin held at a firm 20%. The issue was on the top line, as full year revenue guidance moved lower...

      Nov 4Yahoo FinanceBVS
      Adeia Posts Downbeat Q3 Earnings, Joins Bioventus, Apple And Other Big Stocks Moving Lower In Tuesday’s P
      Nov 3BenzingaADEABVS
      Bioventus Inc (BVS) Q3 2026 Earnings Call Highlights: Solid Pain and Ultrasonics Growth Offset ...
      Nov 3Yahoo FinanceBVS
      Bioventus Q3 Earnings Call Highlights
      Nov 2Yahoo FinanceBVS
      Bioventus: Q3 Earnings Snapshot
      Nov 2Yahoo FinanceBVS
      Bioventus Q3 2026 slides: margin gains offset by revenue miss
      Nov 2Investing.comBVS
      Bioventus Q3 2026 Earnings Call Transcript
      Nov 2BenzingaBVS
      Earnings call transcript: Bioventus Q3 2026 revenue miss sparks sharp selloff
      Nov 2Investing.comBVS
      Bioventus (BVS) Matches Q3 Earnings Estimates
      Nov 2Yahoo FinanceBVS
      Bioventus earnings beat by $0.01, revenue fell short of estimates
      Nov 2Investing.comBVS
      Analysts Are Bullish on These Healthcare Stocks: Bioventus (BVS), Regeneron (REGN)

      Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

      Oct 29The Globe and MailBVSREGN
      Bioventus: Cash Flow Anchors The Bull Case Beyond A Potential Sale (NASDAQ:BVS)

      Bioventus benefits from improved financing flexibility, with a term loan maturity extended to 2030 and a 75 bps interest margin reduction. See why BVS is a Buy.

      Sep 21Seeking AlphaBVS
      Are Medical Stocks Lagging Bioventus (BVS) This Year?

      Here is how Bioventus (BVS) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

      Aug 24Yahoo FinanceBVS

      This is the newest page. Registered accounts read further back.